• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肢体骨肉瘤的治疗:里佐利骨科研究所20年的经验

The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli.

作者信息

Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A, Franceschi C

出版信息

Cancer. 1981 Oct 1;48(7):1569-81. doi: 10.1002/1097-0142(19811001)48:7<1569::aid-cncr2820480717>3.0.co;2-x.

DOI:10.1002/1097-0142(19811001)48:7<1569::aid-cncr2820480717>3.0.co;2-x
PMID:6945143
Abstract

Twenty year's (1959-1979) experience in the treatment of osteosarcoma at the Bone Tumor Center of the Istituto Ortopedico Rizzoli is presented. During this period 433 cases were recorded, but only 266 were considered. All the patients underwent surgery but after 1970 whole-lung irradiation (1971), immunotherapy (1971), and chemotherapy (1972 onward) were added as adjuvant therapies on a nonrandomized basis. In the group treated with surgery alone the prognosis was very poor: 10% survived nine years or more after the diagnosis, an average disease-free interval of 7.7 months and an average survival time of 13 months. Monolateral whole-lung irradiation had negative results and was abandoned after six cases. Adjuvant immunotherapy with irradiated autologous tumor cells gave moderately positive results in 16 patients, but only by delaying the appearance of first metastases, therefore increasing the time of survival. Adjuvant chemotherapy was performed with three different protocols: one protocol with ADM only and two protocols using VCR + MTX (at medium dose) + ADM, administered according to two different schedules. Superimposable results were obtained with these three regimens. With equal follow-up, the percentage of continuously disease-free patients treated with adjuvant chemotherapy was significantly higher than that of patients treated with surgery alone (P less than 0.001). The patients in the chemotherapy group who had relapses showed a prolonged time (mean = 12.3 months) to the onset of the first metastasis. Adjuvant chemotherapy caused virtually no morbidity and no deaths. Reference is made to the advantages of a large and homogeneous caseload deriving from a single institution to avoid preselection bias and evaluate the effectiveness of new therapeutic approaches when patient randomization has not been employed.

摘要

本文介绍了里佐利骨科研究所骨肿瘤中心二十年(1959 - 1979年)来治疗骨肉瘤的经验。在此期间共记录了433例病例,但仅对其中266例进行了分析。所有患者均接受了手术治疗,1970年后,在非随机的基础上增加了全肺照射(1971年)、免疫治疗(1971年)和化疗(1972年起)作为辅助治疗。单纯手术治疗组的预后非常差:10%的患者在诊断后存活九年或更长时间,平均无病生存期为7.7个月,平均生存时间为13个月。单侧全肺照射效果不佳,在治疗6例后被放弃。用经照射的自体肿瘤细胞进行辅助免疫治疗,16例患者取得了中度阳性结果,但仅通过延迟首次转移的出现,从而延长了生存时间。辅助化疗采用三种不同方案:一种仅含阿霉素的方案,两种使用长春新碱+甲氨蝶呤(中等剂量)+阿霉素的方案,并按照两种不同的给药时间表进行给药。这三种方案取得了相似的结果。在相同的随访期内,接受辅助化疗的持续无病患者百分比显著高于单纯手术治疗的患者(P < 0.001)。化疗组中复发的患者出现首次转移的时间延长(平均 = 12.3个月)。辅助化疗几乎未引起任何并发症和死亡。文中提到了来自单一机构的大量且同质病例的优势,即在未采用患者随机分组的情况下,可避免预选择偏倚并评估新治疗方法的有效性。

相似文献

1
The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli.肢体骨肉瘤的治疗:里佐利骨科研究所20年的经验
Cancer. 1981 Oct 1;48(7):1569-81. doi: 10.1002/1097-0142(19811001)48:7<1569::aid-cncr2820480717>3.0.co;2-x.
2
The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future.肢体非转移性高级别骨肉瘤的治疗:意大利里佐利经验回顾。对未来的影响。
Cancer Treat Res. 2009;152:275-87. doi: 10.1007/978-1-4419-0284-9_14.
3
Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.肢体骨肉瘤伴同步肺转移的新辅助化疗:顺铂、阿霉素、大剂量甲氨蝶呤和异环磷酰胺治疗。
Oncol Rep. 2000 Mar-Apr;7(2):339-46. doi: 10.3892/or.7.2.339.
4
Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin.肢体骨肉瘤的初始化疗与延迟手术(新辅助化疗)。里佐利研究所对127例术前接受静脉注射甲氨蝶呤(高剂量与中等剂量)和动脉内顺铂治疗患者的经验。
Cancer. 1990 Jun 1;65(11):2539-53. doi: 10.1002/1097-0142(19900601)65:11<2539::aid-cncr2820651125>3.0.co;2-m.
5
Surgery of osteosarcoma of the extremities: indications and complications in the recent experience at the Istituto Ortopedico Rizzoli.肢体骨肉瘤的手术治疗:里佐利骨科研究所近期经验中的适应证及并发症
Cancer Treat Res. 1993;62:185-203. doi: 10.1007/978-1-4615-3518-8_22.
6
Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy.144例接受联合治疗的局限性尤因肉瘤患者的长期结果。
Cancer. 1989 Apr 15;63(8):1477-86. doi: 10.1002/1097-0142(19890415)63:8<1477::aid-cncr2820630805>3.0.co;2-8.
7
The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute.动脉内注射与静脉注射顺铂在肢体骨肉瘤新辅助治疗中的效果:里佐利研究所的经验
Chir Organi Mov. 1996 Sep-Dec;81(4):369-82.
8
Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy.伴有同步肺转移的四肢骨肉瘤:44例接受新辅助化疗患者的长期结果
J Chemother. 1998 Feb;10(1):69-76. doi: 10.1179/joc.1998.10.1.69.
9
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.两种方案治疗泰国儿童骨肉瘤的比较结果:单机构经验中高剂量甲氨蝶呤(HDMTX)的作用。
Asian Pac J Cancer Prev. 2014;15(22):9823-9. doi: 10.7314/apjcp.2014.15.22.9823.
10
Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients.接受新辅助或辅助化疗的骨肉瘤患者的骨转移:里佐利对52例患者的经验。
Acta Orthop. 2006 Dec;77(6):938-43. doi: 10.1080/17453670610013268.

引用本文的文献

1
The Diagnosis and Treatment of Osteosarcoma and Ewing's Sarcoma in Children and Adolescents.儿童和青少年骨肉瘤和尤文肉瘤的诊断和治疗。
Dtsch Arztebl Int. 2023 Jun 16;120(24):405-412. doi: 10.3238/arztebl.m2023.0079.
2
Exploring the landscape of immunotherapy approaches in sarcomas.探索肉瘤免疫治疗方法的前景。
Front Oncol. 2023 Jan 9;12:1069963. doi: 10.3389/fonc.2022.1069963. eCollection 2022.
3
Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.骨肉瘤的辅助和新辅助化疗:历史观点。
Adv Exp Med Biol. 2020;1257:1-10. doi: 10.1007/978-3-030-43032-0_1.
4
Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison.骨肉瘤诊断时转移的发生率:一项国际比较
Pediatr Blood Cancer. 2016 Jun;63(6):1006-11. doi: 10.1002/pbc.25963. Epub 2016 Feb 29.
5
The efficacy of high-dose versus moderate-dose chemotherapy in treating osteosarcoma: a systematic review and meta-analysis.高剂量与中剂量化疗治疗骨肉瘤的疗效:一项系统评价和荟萃分析。
Int J Clin Exp Med. 2015 Sep 15;8(9):15967-74. eCollection 2015.
6
Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma.高剂量与标准剂量化疗治疗原发性高分化骨肉瘤的系统评价
Tumour Biol. 2014 Oct;35(10):10419-27. doi: 10.1007/s13277-014-2253-x. Epub 2014 Jul 23.
7
What are the factors that affect survival and relapse after local recurrence of osteosarcoma?影响骨肉瘤局部复发后生存和复发的因素有哪些?
Clin Orthop Relat Res. 2014 Oct;472(10):3188-95. doi: 10.1007/s11999-014-3759-7. Epub 2014 Jul 1.
8
Current therapeutic strategies and novel approaches in osteosarcoma.当前骨肉瘤的治疗策略和新方法。
Cancers (Basel). 2013 May 24;5(2):591-616. doi: 10.3390/cancers5020591.
9
Expression of the chemokine receptor CXCR7 in CXCR4-expressing human 143B osteosarcoma cells enhances lung metastasis of intratibial xenografts in SCID mice.CXCR4 表达的人 143B 骨肉瘤细胞中趋化因子受体 CXCR7 的表达增强了 SCID 小鼠胫骨内异种移植物的肺转移。
PLoS One. 2013 Sep 10;8(9):e74045. doi: 10.1371/journal.pone.0074045. eCollection 2013.
10
Long-term survivals of stage IIb osteosarcoma: a 20-year experience in a single institution.单中心 20 年经验:Ⅱb 期骨肉瘤的长期生存
Clin Orthop Surg. 2011 Mar;3(1):48-54. doi: 10.4055/cios.2011.3.1.48. Epub 2011 Feb 15.